Relmada Gets FDA Fast-Track Designation for REL-1017 as MDD Monotherapy
09 Agosto 2022 - 10:21AM
Dow Jones News
By Colin Kellaher
Relmada Therapeutics Inc. on Tuesday said the U.S. Food and Drug
Administration granted fast-track designation to REL-1017, the
company's lead program, as a monotherapy for the treatment of major
depressive disorder, or MDD.
The Coral Gables, Fla., clinical-stage biotechnology company,
which is currently conducting Phase 3 studies of REL-1017 as
monotherapy and adjunctive therapy for the mental-health disorder,
said available treatments remain inadequate for the majority of
patients with MDD.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
needs.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 09, 2022 09:06 ET (13:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Relmada Therapeutics (NASDAQ:RLMD)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Relmada Therapeutics (NASDAQ:RLMD)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
